Medifast, Inc. MED
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -47.05% | -34.03% | -36.31% | -35.96% | -36.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -47.05% | -34.03% | -36.31% | -35.96% | -36.29% |
| Cost of Revenue | -22.97% | -44.11% | -46.32% | -47.19% | -48.40% |
| Gross Profit | -36.86% | -55.67% | -55.04% | -52.09% | -49.96% |
| SG&A Expenses | -26.72% | -48.92% | -50.67% | -47.95% | -51.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.03% | -27.56% | -32.15% | -31.87% | -36.28% |
| Operating Income | -358.88% | -266.99% | -398.25% | -192.40% | -37.29% |
| Income Before Tax | -341.96% | -280.91% | 25.07% | -178.70% | -62.03% |
| Income Tax Expenses | 455.01% | 359.75% | 4,577.45% | 691.86% | -56.56% |
| Earnings from Continuing Operations | -1,030.29% | -741.59% | -153.87% | -884.46% | -65.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9,511.69% | -803.74% | -186.19% | -992.54% | -96.61% |
| EBIT | -358.88% | -266.99% | -398.25% | -192.40% | -37.29% |
| EBITDA | -134.75% | -129.39% | -121.07% | -99.89% | -12.47% |
| EPS Basic | -16,408.85% | -801.48% | -184.77% | -979.45% | -96.65% |
| Normalized Basic EPS | -321.67% | -188.28% | -321.44% | -138.21% | 12.17% |
| EPS Diluted | -39,369.15% | -829.90% | -181.48% | -1,049.97% | -98.57% |
| Normalized Diluted EPS | -322.85% | -188.67% | -324.82% | -138.58% | 12.43% |
| Average Basic Shares Outstanding | 1.01% | 0.71% | 0.50% | 0.46% | 0.44% |
| Average Diluted Shares Outstanding | 0.75% | 0.37% | 0.48% | 0.32% | 0.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -1.01% | -1.12% | 0.85% | -1.03% | -0.69% |